首页 | 本学科首页   官方微博 | 高级检索  
     


Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease
Authors:Massimo Breccia  Laura Cannella  Caterina Stefanizzi  Michelina Santopietro  Rosa De Cuia  Daniela Diverio  Giuliana Alimena
Affiliation:1. Ematologia-Sapienza Università, Roma, Italy;2. Ematologia, Ospedale Cardarelli, Napoli, Italy;3. Ematologia e Dipartimento Oncologia Medica, Spedali Civili, Brescia, Italy;4. Ematologia, Ospedale S. Giuseppe Moscati, Taranto, Italy;5. UOC Ematologia-IRCSS Istituto Tumori Giovanni Paolo II-Bari, Italy;6. Ematologia-Azienda Ospedaliero-Universitaria, Policlinico consorziale di Bari, Italy;7. Ematologia, A.O.U. Città della salute e della scienza di Torino, Italy;8. Ematologia-Ospedale Seragnoli, Università di Bologna, Italy;9. Oncoematologia, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano, Italy;10. Ematologia, Ospedale S. Giovanni, Roma, Italy;11. Ematologia, Lecce, Italy;12. Ematologia-Università Cattolica, Roma, Italy;13. Ematologia e Medicina Interna, Università di Torino, Orbassano, Italy;14. Ematologia, Dipartimento di Scienze Mediche, Università di Cagliari, Italy;15. Ematologia-Azienda Ospedaliero Universitaria, Ospedale Riuniti Ancona, Italy;p. Ematologia e Medicina Trasfusionale, Tricase, Italy;q. Ematologia, Università Tor Vergata, Roma, Italy;r. Ematologia e CTMO, Azienda Ospedaliero Universitaria, Parma, Italy;s. Ematologia, Fondazione IRCSS Policlinico San Matteo, Pavia, Italy;t. Ematologia, Ospedale Ferrarotto, Catania, Italy;u. Ematologia, Università Federico II, Napoli, Italy;v. Ematologia, Ospedale S. Eugenio, Roma, Italy;w. Ematologia, Università di Siena, Italy;1. Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki City, Nagasaki, Japan;2. Nagasaki CML Study Group, Nagasaki, Japan;3. Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, Japan;4. Laboratory of Hematoimmunology, Department of Clinical Laboratory Sciences, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa, Japan;5. Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan;1. Department of Internal Medicine, Tygerberg Academic Hospital, University of Stellenbosch, Cape Town, South Africa;2. Department of Pathology, National Health Laboratory Services (NHLS), University of Stellenbosch and Pathcare Laboratories, Cape Town, South Africa;3. Department of Medicine, Columbia University Medical Center, New York, NY;4. Department of Medicine, University of the Free State, Bloemfontein and Panorama Mediclinic, Cape Town, South Africa;5. Department of Haematology and Molecular Medicine, University of the Witwatersrand, Johannesburg, South Africa;1. Institute of Translational Medicine, University of Liverpool, Liverpool, UK;2. Cancer Research UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, UK;3. Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK;4. East Kent Hospitals, Canterbury, UK;5. Department of Haematology, St James''s Hospital, Leeds, UK;6. Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK;7. Department of Haematological Medicine, Kings College Hospital, London, UK;8. Northern Institute for Cancer Research, Newcastle University, Newcastle, UK;9. Paul O''Gorman Leukaemia Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK;1. Clinic of Hematology and Clinical Immunology, Clinical Centre Ni?, Ni?, Serbia;2. Faculty of Medicine, University of Ni?, Ni?, Serbia;3. Mechanical Engineering Faculty, University of Ni?, Ni?, Serbia
Abstract:Chronic myeloid leukaemia (CML) patients in chronic phase (CP) are currently treated with a standard dose of imatinib of 400 mg/daily. However, once in complete cytogenetic remission (CCR) it is possible that some patients maintain this status with reduced dose of the drug. Here, we describe five cases of CML in late CP, which were switched to imatinib while in CCR after interferon alpha (IFNα) and reached complete and stable molecular remission with intermittent drug administration at 400 mg/every 20 days/month.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号